Hepatocellular carcinoma post direct anti hepatitis C viral agents; clinical features
Afr. J. Gastroenterol. Hepatol
;
5(2): 5-15, 2022. tables
Artigo
em Inglês
| AIM
| ID: biblio-1512875
ABSTRACT
Background:
Direct Anti Hepatitis C Viral Agents (DAAs) were introduced for Hepatitis C Virus (HCV) infection management, which resulted in high sustained virological response (SVR) in many countries and a low failure rate. However, hepatocellular carcinoma (HCC) post DAAs therapy is controversial; few studies related aggressive pattern HCC to DAAs. Therefore, we aimed to study the hepatocellular carcinoma relation to direct anti-hepatitis C viral drugs. Patients andMethods:
This observational cross-sectional study included 67 adults Egyptian HCC patients associated with HCV diagnosed at the Zagazig University Hospitals, who were divided into two groups according to DAAs treatment.Results:
HCC is more common in male patients (77.6%) of all studied cases, and those are treated by DAAs (62.7%). The median age of HCC post-DAA was 63(48-83), while 58 (45-75) in HCC patients without DAA, with no significant difference p= 0.053. HCC presented in the non-DAAs treated group, mainly decompensating by hematemesis (HM) (32%). While in the post-DAAs group, HCC was significantly diagnosed primarily with abdominal pain at 31%. There is no significant difference as regards the liver status with frequent liver cirrhosis in both groups, 14(56%) and 32(76.2%).Conclusion:
DAAs therapy of HCV added no specific pattern association for hepatocellular carcinoma.
Texto completo:
DisponíveL
Índice:
AIM (África)
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Afr. J. Gastroenterol. Hepatol
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Clinical Oncology Department, Faculty of Medicine, Zagazig University/EG
/
Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt/EG
/
Tropical Department, Faculty of Medicine, Zagazig University, Egypt/EG
Similares
MEDLINE
...
LILACS
LIS